AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04123652
Drug: Lidocaine Hydrochloride 2% Intravenous Solution, DIN 02421992
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: An intravenous will be started. • Lidocaine - initial dose of 5.0 mg/kg +/- 1.0 mg/kg (based on actual weight, up to maximum dose 600 mg) over 45 minutes, followed by increases of 0.5 mg/kg each infusion based on tolerability of side effects, not to exceed 7 mg/kg or 600 mg.~• Ketamine - initial dose of 0.1 mg/kg (based on actual weight) over 45 minutes (rounded to nearest 5 mg, up to maximum 15 mg), increased by 0.1 mg/kg (rounded to nearest 5 mg) each infusion based on tolerability of side effects During the infusion patient will be monitored by another MD for BP, PR, PO2. Patients will not be allowed to drive for 24 hours.
Trial: NCT02140450
Drug: Brimonidine
RxNorm normalized name: Brimonidine
DrugBank: Brimonidine (DB00484)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Brimonidine eyedrop, 2 drops 5 minutes apart, 1-2 hours before intravitreal injection
Trial: NCT02140450
Drug: Acetazolamide
RxNorm normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetazolamide tablet, 2 tabs, 2 hours before intravitreal injection
Trial: NCT02140450
Drug: Mannitol
RxNorm normalized name: Mannitol
DrugBank: Mannitol (DB00742)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous mannitol, 1.5 gram/kg, 1 hour before intravitreal injection
Trial: NCT03687073
Drug: Indole-3-Carbinol
RxNorm normalized name: Indole-3-carbinol
DrugBank: Indole-3-carbinol (DB12881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohorts 2, 3, \& 4: 400 mg PO BID
Trial: NCT03687073
Drug: Silibinin
RxNorm normalized name: Silibinin
DrugBank: Silibinin (DB09298)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohorts 1 \& 4: 720mg
Trial: NCT03687073
Drug: Silibin
RxNorm normalized name: Silibinin
DrugBank: Silibinin (DB09298)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort 3: 360mg
Trial: NCT04291248
Drug: Anlotinib
RxNorm normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A multi-target receptor tyrosine kinase inhibitor.
Trial: NCT01350921
Drug: Ticagrelor
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 90 mg oral immediate release tablets, single dose on days 1 and 9
Trial: NCT00086970
Drug: ifosfamide
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00086970
Drug: O6-benzylguanine
RxNorm normalized name: O6-benzylguanine
DrugBank: 6-O-benzylguanine (DB11919)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02495220
Drug: SB dexmedetomidine bupivacaine block
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SB block with 0.05 mL/kg of 0.5%bupivacaine and 0.5µ/kg dexmedetomidine mixture
Trial: NCT02495220
Drug: intravenous dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: received 1µ/kg IV dexmedetomidine
Trial: NCT03781843
Drug: Genicular nerve block with lidocaine
RxNorm normalized name: Ivy Block
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The color doppler ultrasound-guided genicular nerve block at the site of the superior lateral, the superior medial, and the inferior medial genicular nerves.
Trial: NCT03781843
Drug: Genicular nerve block with saline
RxNorm normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The color doppler ultrasound-guided genicular nerve block at the site of the superior lateral, the superior medial, and the inferior medial genicular nerves.
Trial: NCT03781843
Drug: Genicular nerve block with dextrose
RxNorm normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The color doppler ultrasound-guided genicular nerve block at the site of the superior lateral, the superior medial, and the inferior medial genicular nerves.
Trial: NCT00365261
Drug: Eszopiclone
RxNorm normalized name: Eszopiclone
DrugBank: Eszopiclone (DB00402)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: eszopiclone 2 to 3 mg po at bedtime
Trial: NCT01236833
Drug: Lactated Ringer's Solution
RxNorm normalized name: Lactated Ringer's Solution Intravenous Solution
DrugBank: Potassium chloride (DB00761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2.5 ml per kg every 3 hours, via nasogastric tube, orogastric tube or orally, until the infant reaches 80 ml/kg/day of milk feeding or for a maximum of 14 days
Trial: NCT00788528
Drug: S-2367 (velneperit)
RxNorm normalized name: TPG-S
DrugBank: S-23 (DB07419)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, 4 x 400 mg, taken once daily with morning meal, 54-weeks
Trial: NCT01802086
Drug: Emla-cream
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical anaesthetic
Trial: NCT00593879
Drug: Mecamylamine
RxNorm normalized name: Mecamylamine
DrugBank: Mecamylamine (DB00657)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2.5mg mecamylamine Hcl, tablet form taken twice a day (total of 5.0mg). For 7.5 mg dose group, 2 tablets taken morning, one tablet evening. At 10.0mg, 2 tablets taken twice daily.
Trial: NCT02833350
Drug: GDC-0853
RxNorm normalized name: calcium carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive GDC-0853 at low, mid, or high doses, orally once or twice daily for 12 weeks in Cohort 1 or 2.
Trial: NCT02833350
Drug: Adalimumab
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks.
Trial: NCT02833350
Drug: MTX
RxNorm normalized name: MTX
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines).
Trial: NCT00523393
Drug: Insulin Glargin
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Titration of bedtime insulin glargin aiming at normal morning fasting glucose
Trial: NCT04432506
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT03562832
Drug: PARP inhibitor 2X-121
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: 2X-121 (DB16063)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg PARP inhibitor 2X-121 as single daily oral agent in mBC patients
Trial: NCT00523393
Drug: Human Insulin
RxNorm normalized name: Human insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Titration of bedtime human insulin aiming at normal morning fasting glucose
Trial: NCT01973114
Drug: Latanoprost
RxNorm normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01937468
Drug: Interleukin-2
RxNorm normalized name: INTERLEUKIN-2
DrugBank: Human interleukin-2 (DB14865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interleukin-2: Starting the day of Treg-enriched cell infusion, each participant will receive daily subcutaneous IL-2 for self-administration for 8 weeks, followed by a 4-week hiatus. IL-2 will be administered on an outpatient basis. Expected toxicities and potential risks as well as dose modifications are described in Section 6 (Expected Toxicities and Dosing Delays/Dose Modification).
Trial: NCT04153253
Drug: Aflibercept Injection [Eylea]
RxNorm normalized name: aflibercept Injection [Eylea]
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Three monthly based intravitreal injections were given followed by PRP if the hemorrhage was sufficiently cleared.Intravitreal injection was done in sterile operating room, after sterilization and toweling with application of sterile speculum, Betadine 5% drops was instilled into the conjunctiva and kept for two minutes followed by wash with balanced salt solution. Injection of 2mg /0.05m aflibercept was given 4 mm from the limbus in phakic eyes and 3.5 mm in pseudophakic with compression by sterile cotton tip on the site of injection, Paracentesis was done in cases of very high IOP following injection. At the end of procedure check of visual acuity was done (to be at least light perception).~PRP was done if the hemorrhage is sufficiently cleared after the third injection.
Trial: NCT02648347
Drug: Vadadustat
RxNorm normalized name: vadadustat
DrugBank: Vadadustat (DB12255)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Oral dose administered once daily for ≥36 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.
Trial: NCT03830385
Drug: PaclitaxelPaclitaxel (Albumin Bound),Bleomycin combined with Cisplatin or Carboplatin
DrugBank: Bleomycin (DB00290)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All patients enrolled in the study will accept Paclitaxel (Albumin Bound),Bleomycin combined with Cisplatin or Carboplatin as their firstline chemotherapy
Trial: NCT01585805
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01585805
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01585805
Drug: Gemcitabine Hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01585805
Drug: Veliparib
RxNorm normalized name: veliparib
DrugBank: Veliparib (DB07232)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT00253396
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00253396
Drug: Enoxaparin
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03327012
Drug: Treatment of Panlongqi Tablet
RxNorm normalized name: OIL OF CAMPHOR
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Panlongqi Tablet:1.2g,3times a day, oral, for 4 weeks.
Trial: NCT00075595
Drug: irinotecan hydrochloride
RxNorm normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00778544
Drug: amoxicillin-clavulanic acid 600 mg- 42.9 mg/ 5 mL oral suspension
DrugBank: Clavulanic acid (DB00766)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01957774
Drug: THR-18
RxNorm normalized name: THR-184
DrugBank: THR-184 (DB19097)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: THR-18 is an 18-mer peptide derived from the sequence of human plasminogen activator inhibitor 1 (PAI-1), having the ability to bind to a site of tissue plasminogen activator (tPA) distal to its catalytic site and uncouple the beneficial clot-dissolving properties of tPA from its deleterious non-fibrinolytic effects.
Trial: NCT02650635
Drug: TLR8 Agonist VTX-2337
RxNorm normalized name: VTX-801
DrugBank: VTX-801 (DB17646)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given SC
Trial: NCT00569465
Drug: Acetylcysteine
RxNorm normalized name: Acetylcysteine
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 600 mg twice a day
Trial: NCT01826773
Drug: CardioPET™
DrugBank: Cardiopet (DB18913)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CardioPET™ will be intravenously injected to each subject as a single radio-labeled dose of up to 8 mCi (296 MBq).
Trial: NCT00804622
Drug: telbivudine
RxNorm normalized name: Telbivudine
DrugBank: Telbivudine (DB01265)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: daily oral administration,600mg,over 12 weeks
Trial: NCT00804622
Drug: tenofovir disproxil fumarate
RxNorm normalized name: Tenofovir Disoproxil Fumarate
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: daily oral administration,300mg,over 12 weeks
Trial: NCT00804622
Drug: telbivudine plus tenofovir disproxil fumarate
RxNorm normalized name: Tenofovir Disoproxil Fumarate
DrugBank: Telbivudine (DB01265)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: daily oral administration of telbivudine 600 mg and tenofovir disproxil fumarate 300 mg in combination given over 12 weeks
Trial: NCT01387620
Drug: Hyaluronic Acid and hydroxypropylmethylcellulose
DrugBank: Propyl acetate (DB01670)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyaluronic Acid 1.6% was used to performed phacoemulsification in one eye and hydroxypropylmethylcellulose 2% was used in the fellow eye.
Trial: NCT02508857
Drug: Magnesium
RxNorm normalized name: Magnesium
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients received intravenous magnesium sulfate (20 mg/kg) in bolus, then magnesium sulfate (2 mg/kg/h) was continuously injected during the procedure (Group M)
Trial: NCT02508857
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intravenous saline solution (20 ml) was injected in bolus, followed by continuous infusion of saline solution during the entire procedure (Group S).
Trial: NCT02484833
Drug: Cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00333840
Drug: imatinib mesilate
RxNorm normalized name: Imatinib mesilate
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: imatinib supplied as 100 mg and 400 mg tablets or 100 mg capsules.
Trial: NCT00333840
Drug: interferon-alpha (INF-a)
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: interferon-alpha (IFN-a) subcutaneous (SC) injections escalated over 4 weeks to achieve a target dose of 5 MU/m\^2/day.
Trial: NCT00333840
Drug: cytarabine (ARA-C)
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: cytarabine 20 mg/m\^2/day (max 40 mg) SC for 10 days every month.
Trial: NCT02277730
Drug: phenylephrine
RxNorm normalized name: Phenylephrine
DrugBank: Phenylephrine (DB00388)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02277730
Drug: ephedrine
RxNorm normalized name: Ephedrine
DrugBank: Ephedrine (DB01364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02328183
Drug: Polymyxin B
RxNorm normalized name: Polymyxin B
DrugBank: Polymyxin B (DB00781)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: administrate drug by 0.75-1.25 mg/kg/dose intravenously q 12 hrs both saline and dextrose solution can be dissolved duration 7-14 days
Trial: NCT04382300
Drug: pyrotinib combined with thalidomide
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single Group Assignment
Trial: NCT03758443
Drug: TD-1473 Dose C
RxNorm normalized name: Vitamin C
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: See Arm description
Trial: NCT04675177
Drug: Polidocanol foam sclerotherapy
RxNorm normalized name: polidocanol Injectable Foam
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: i. Patients underwent preparation, two hours before the intervention, with cleaning enema (Disodium phosphate). No antibiotic prophylaxis was prescribed.~ii. Preparation of the polidocanol (Aethoxysklerol 3%) foam according to Tessari technique immediately before application, so that the microbubbles of the foam did not disintegrate; iii. The procedure was performed in the medical office. Application according to the Blanchard technique through a disposable transparent anoscope, in jackknife position, using a 20mL disposable syringe of the mixture (polidocanol + air) and a reusable 10 cm syringe extender adapted to an intravenous needle; iv. Patients were treated in a maximum of 3 sessions, at 3 weeks intervals; v. Maximum dose per treatment session of 20mL of mixture of 4mL of polidocanol 3% with 16mL of air; i. In each session, the sclerosant was injected in one or more hemorroidary cushion;
Trial: NCT01649804
Drug: tocilizumab [RoActemra/Actemra]
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 8 mg/kg intravenously every 4 weeks for 104 weeks
Trial: NCT04432259
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 4 mg bid for 4 days
Trial: NCT02527993
Drug: Glucobay (acarbose)
RxNorm normalized name: Acarbose
DrugBank: Acarbose (DB00284)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Se arm description
Trial: NCT02527993
Drug: Januvia (sitagliptin)
RxNorm normalized name: Januvia
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Se arm description
Trial: NCT02527993
Drug: Verapamil HEXAL (verapamil)
DrugBank: Verapamil (DB00661)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Se arm description
Trial: NCT02527993
Drug: Victoza (liraglutide)
RxNorm normalized name: Victoza
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Se arm description
Trial: NCT02527993
Drug: Signifor (pasireotide)
RxNorm normalized name: Signifor
DrugBank: Pasireotide (DB06663)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Se arm description
Trial: NCT03590873
Drug: Vasopressin
RxNorm normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vasopressin, is a hormone synthesized as a peptide prohormone in neurons in the hypothalamus, and is converted to arginine vasopressin. It then travels down the axon of that cell, which terminates in the posterior pituitary, and is released from vesicles into the circulation in response to extracellular fluid hypertonicity (hyperosmolality). Arginine vasopressin has two primary functions. First, it increases the amount of solute-free water reabsorbed back into the circulation from the filtrate in the kidney tubules of the nephrons. Second, arginine vasopressin constricts arterioles, which increases peripheral vascular resistance and raises arterial blood pressure.
Trial: NCT00471146
Drug: AG-013736
RxNorm normalized name: AGS-499
DrugBank: AGS-499 (DB18058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration, starting dose 5 mg twice daily \[BID\] every day until unacceptable toxicity or tumor progression.
Trial: NCT00471146
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: intravenous administration at 1,000 mg/m\^2 day 1, day 8 and day 15 every 4 weeks (conventional dose) until unacceptable toxicity or tumor progression.
Trial: NCT02387710
Drug: Tiagabine
RxNorm normalized name: Tiagabine
DrugBank: Tiagabine (DB00906)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GABA reuptake inhibitor
Trial: NCT04402060
Drug: APL-9
RxNorm normalized name: APL-9
DrugBank: APL-9 (DB16460)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complement (C3) Inhibitor
Trial: NCT00120523
Drug: Pimecrolimus
RxNorm normalized name: Pimecrolimus
DrugBank: Pimecrolimus (DB00337)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pimecrolimus cream 1 %
Trial: NCT00245661
Drug: Temazepam
RxNorm normalized name: Temazepam
DrugBank: Temazepam (DB00231)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00563355
Drug: erythropoietin
RxNorm normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00000488
Drug: cholestyramine
RxNorm normalized name: Cholestyramine
DrugBank: Cholestyramine (DB01432)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000304
Drug: Dextroamphetamine
RxNorm normalized name: Dextroamphetamine
DrugBank: Dextroamphetamine (DB01576)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg for first 8 weeks and 30 mg for 2nd 8 weeks
Trial: NCT00000304
Drug: D-Amphetamine
RxNorm normalized name: d-amphetamine
DrugBank: Dextroamphetamine (DB01576)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg for the first 8 weeks and 60 for the second 8 weeks (16 weeks total)
Trial: NCT03141593
Drug: Vitamin D: liquid form, start weekly
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient will start treatment with weekly schedule, and switch after 3 months to monthly schedule for another 3 months.
Trial: NCT03141593
Drug: Vitamin D: liquid form, start monthly
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient will start treatment with monthly schedule, and switch after 3 months to weekly schedule for another 3 months.
Trial: NCT03141593
Drug: Vitamin D: solid form, start weekly
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient will start treatment with weekly schedule, and switch after 3 months to monthly schedule for another 3 months.
Trial: NCT04928651
Drug: Clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clonidine will be administered to preterm infants in need of analgesia and sedation; either as the primary drug for comfort and light sedation or as an add-on drug to opioids according to an algorithm based on pain and sedative scoring results. Opioids are mostly given to postoperative patients. These drugs (morphine or fentanyl) will not be studied, but a baseline PK sample will be taken to correlate to the baseline aEEG.
Trial: NCT03141593
Drug: Vitamin D: solid form, start monthly
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient will start treatment with monthly schedule, and switch after 3 months to weekly schedule for another 3 months.
Trial: NCT01004770
Drug: GE-145 (AN113111) Injection
RxNorm normalized name: gE recombinant Varicella zoster virus (VZV) glycoprotein E
DrugBank: Varicella zoster vaccine (recombinant) (DB13924)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 healthy volunteers (10 per treatment group) will receive AH113111 320 mg I/mL at 1 of 4 possible doses (300, 450, 600, or 900 mg I/kg) as a single intravenous (IV) administration.